About Us
what we do
We enable biological engineering at a genome-scale
We provide our partners with groundbreaking synthetic DNA and cell engineering services to investigate novel therapeutics, develop more sustainable products, and conduct otherwise unapproachable scientific research.
Neochromosome is uniquely suited to accelerate this work. Our first-in-class capabilities were developed to design, build, and test the world’s first fully synthetic eukaryotic cells. Today, we offer our services and platform — from highly automated synthesis of complex DNA to de novo design, synthesis, and delivery of chromosomes – to researchers and organizations around the world.
Neo is a subsidiary of Opentrons Labworks. Neo leverages Opentrons’ robotics and automation for its world class genome foundry.
Our Team
Neo leadership and advisors bring together industry-leading expertise in genome-scale engineering approaches and therapeutic technologies.
Leslie Mitchell, PhD
GM & CEO
Gregg McConnell
Chief Business Officer
Steven Riedmuller
VP Commercial Operations
Alfie Umbhau
VP Product
John Anderson, PhD
VP Software
Albert Serra Cardona, PhD
Microbial Engineering Team Lead
Akil Hamza, PhD
Foundry Team Lead
Megan Hogan, PhD
Mammalian Engineering Team Lead
Jeff Spencer, PhD
Protein Engineering Team Lead
Jon Brennan-Badal
CEO, Opentrons Labworks
Myrtle Potter
Board Chair, Opentrons Labworks
Robert Langer, ScD
Chair, Scientific Advisory Board
Vinod Khosla
Advisor, Opentrons Labworks
Joel Bader, PhD
Co-Founder & Advisor
Jef Boeke, PhD
Co-Founder & Advisor